| scholarly article | Q13442814 |
| P2093 | author name string | S Gill | |
| R M Goldberg | |||
| R R Thomas | |||
| P2860 | cites work | Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue | Q27863454 |
| A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil | Q28352447 | ||
| Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III | Q28364849 | ||
| Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data | Q31145605 | ||
| Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures | Q33962340 | ||
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 | ||
| Global cancer statistics in the year 2000. | Q34571897 | ||
| Intrahepatic arterial infusion of chemotherapy: pharmacologic principles | Q34598621 | ||
| Mature results from three large controlled studies with raltitrexed ('Tomudex'). | Q36291303 | ||
| Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients | Q36621223 | ||
| Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial | Q39394495 | ||
| Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy | Q43932425 | ||
| UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity | Q43979778 | ||
| Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial | Q44016718 | ||
| Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer | Q44119203 | ||
| Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer | Q44119206 | ||
| Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation | Q44124430 | ||
| Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial | Q44306113 | ||
| Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. | Q54111829 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| chemotherapy | Q974135 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 683-692 | |
| P577 | publication date | 2003-10-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Review article: colorectal cancer chemotherapy | |
| P478 | volume | 18 |
| Q43941230 | 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer |
| Q36695083 | A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma |
| Q38717006 | Anticancer Activity of Punica granatum (Pomegranate): A Review. |
| Q47130946 | Apatinib has anti-tumor effects and induces autophagy in colon cancer cells |
| Q36919283 | Autologous immune enhancement therapy: A case report of a stage IV colonic cancer |
| Q47613947 | Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway |
| Q53682357 | Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction |
| Q37641085 | Clinicopathological and prognostic significance of the microRNA processing enzyme DICER1 mRNA expression in colorectal cancer patients |
| Q42316723 | Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients |
| Q36241935 | Development and progression of colorectal neoplasia |
| Q55456514 | Development of an Experimental Model for Analyzing Drug Resistance in Colorectal Cancer. |
| Q33986725 | Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients |
| Q39831242 | Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. |
| Q59504056 | Germline oncopharmacogenetics, a promising field in cancer therapy |
| Q36486034 | How may anticancer chemotherapy with fluorouracil be individualised? |
| Q92128853 | Hyaluronic acid synthase 2 promotes malignant phenotypes of colorectal cancer cells through transforming growth factor beta signaling |
| Q42363037 | Local staging and assessment of colon cancer with 1.5-T magnetic resonance imaging |
| Q26738528 | Mechanisms of drug resistance in colon cancer and its therapeutic strategies |
| Q38969114 | MiR-381 functions as a tumor suppressor in colorectal cancer by targeting Twist1. |
| Q38586744 | MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma |
| Q33253178 | Molecular determinants of irinotecan efficacy. |
| Q37656158 | Oxaliplatin and Infliximab Combination Synergizes in Inducing Colon Cancer Regression. |
| Q36454362 | Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy |
| Q50317237 | Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients |
| Q52375024 | Smad4 and epithelial-mesenchymal transition proteins in colorectal carcinoma: an immunohistochemical study. |
| Q34111824 | The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy |
| Q36545987 | miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. |
Search more.